⚕ GalenOps field
←

SITE002-0341

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-04-06

AEs
7
Serious
1
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-09 (study day 21); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-31 (study day 43); relationship: Y

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-04 (study day 47); relationship: N

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-06-05 (study day 48); relationship: not assessed

severe serious assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-06-20 (study day 63); relationship: not assessed; serious criteria: hospitalization

mild assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 72); relationship: not assessed

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-08 (study day 81); relationship: not assessed

Data queries

No data queries.